Pennant Group Files 8-K/A Amendment

TL;DR

Pennant Group (PNTG) filed an 8-K/A amendment, updating financial docs from Oct 2.

AI Summary

The Pennant Group, Inc. filed an 8-K/A amendment on December 17, 2025, related to financial statements and exhibits for the period ending October 2, 2025. This amendment, designated as Amendment No. 2, updates information previously reported.

Why It Matters

This filing indicates an update or correction to previously submitted financial information, which could be important for investors assessing the company's financial health.

Risk Assessment

Risk Level: low — This is a routine amendment to a previous filing, not indicating new negative events.

Key Players & Entities

• The Pennant Group, Inc. (company) — Registrant
• October 2, 2025 (date) — Earliest event reported date
• December 17, 2025 (date) — Filing date
• 208-506-6100 (phone_number) — Registrant's principal executive offices phone number

FAQ

Key Financial Figures

• $0.001 — ich registered Common Stock, par value $0.001 per share PNTG Nasdaq Global Select Mar

Filing Documents

• pntg-20251002.htm (8-K/A) — 46KB
• deloitteconsent8-kaxex231.htm (EX-23.1) — 2KB
• deloitteconsent8-kaxex232.htm (EX-23.2) — 2KB
• amedabbrfs2024-ex991.htm (EX-99.1) — 105KB
• lhcabbrfs2024-ex992.htm (EX-99.2) — 104KB
• amedabbrfsq225-ex993.htm (EX-99.3) — 94KB
• lhcabbrfsq225-ex994.htm (EX-99.4) — 92KB
• pntgproformafs-ex995.htm (EX-99.5) — 269KB
• 0001766400-25-000147.txt ( ) — 905KB
• pntg-20251002.xsd (EX-101.SCH) — 2KB
• pntg-20251002_lab.xml (EX-101.LAB) — 22KB
• pntg-20251002_pre.xml (EX-101.PRE) — 13KB
• pntg-20251002_htm.xml (XML) — 3KB

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. (a) Financial Statements of Businesses Acquired. The audited abbreviated financial statements of the acquired Amedisys subsidiaries, which comprise the statement of revenue and direct expenses for the year ended December 31, 2024, the statement of assets acquired and liabilities assumed as of December 31, 2024, and the notes related thereto, together with the Independent Auditors' Report thereon, are filed as Exhibit 99.1 to this Amendment and are incorporated herein by reference. The audited abbreviated financial statements of the acquired UnitedHealth subsidiaries, which comprise the statement of revenue and direct expenses for the year ended December 31, 2024, the statement of assets acquired and liabilities assumed as of December 31, 2024, and the notes related thereto, together with the Independent Auditors' Report thereon, are filed as Exhibit 99.2 to this Amendment and are incorporated herein by reference. The unaudited abbreviated financial statements of the acquired Amedisys subsidiaries, which comprise the statement of revenue and direct expenses for the six months ended June 30, 2025, the statement of assets acquired and liabilities assumed as of June 30, 2025, and the notes related thereto, are filed as Exhibit 99.3 to this Amendment and are incorporated herein by reference. The unaudited abbreviated financial statements of the acquired UnitedHealth subsidiaries, which comprise the statement of revenue and direct expenses for the six months ended June 30, 2025, the statement of assets acquired and liabilities assumed as of June 30, 2025, and the notes related thereto, are filed as Exhibit 99.4 to this Amendment and are incorporated herein by reference. (b) Pro Forma Financial Information. The unaudited pro forma condensed combined financial statements of the Company and the acquired businesses for the six months ended June 30, 2025 and for the year ended December 31, 2024, and the notes related thereto

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: December 16, 2025 THE PENNANT GROUP, INC. By: /s/ LYNETTE B. WALBOM Lynette B. Walbom Chief Financial Officer

View Full Filing

View this 8-K/A filing on SEC EDGAR